Australian biotech company Innate says not subject of Collins investigation


SYDNEY (Reuters) – Australian biotech group Innate Immunotherapeutics Limited (IIL.AX) said on Thursday it was not under investigation in an insider trading case involving Republican U.S. congressman Christopher Collins.

U.S. Rep. Christopher Collins (R-NY) departs the Thurgood Marshall United States Courthouse following his arraignment on insider trading charges in New York, U.S., August 8, 2018. REUTERS/Lucas Jackson

In a statement, the company said it had cooperated fully with requests for information from the U.S. Securities and Exchange Commission (SEC).

“The Company and its…



Read More Here

Be the first to comment on "Australian biotech company Innate says not subject of Collins investigation"

Leave a comment

Your email address will not be published.


*